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Cyclic adenosine 3′,5′-monophosphate (cAMP) modulates a broad range of biological
processes including the regulation of cardiac myocyte contractile function where it
constitutes the main second messenger for β-adrenergic receptors’ signaling to fulfill
positive chronotropic, inotropic and lusitropic effects. A growing number of studies
pinpoint the role of spatial organization of the cAMP signaling as an essential mechanism
to regulate cAMP outcomes in cardiac physiology. Here, we will briefly discuss the
complexity of cAMP synthesis and degradation in the cardiac context, describe the way
to detect it and review the main pharmacological arsenal to modulate its availability.
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Introduction
In cardiomyocytes, the influx of Ca2+ ions through voltage-dependent L-type Ca2+ channels
(LTCC) plays an essential role in cardiac excitability and in coupling excitation to contraction
of these cells. The depolarizing current through LTCC (ICa) contributes to the plateau phase
of the cardiac action potential as well as to pacemaker activity in nodal cells (Shaw and
Colecraft, 2013). This influx of Ca2+ triggers the release of intracellular stores of Ca2+ from
the sarcoplasmic reticulum via the Ryanodine receptor (RyR), which results in activation of
myofilaments contraction. Alterations in density or function of LTCC have been implicated in
a variety of cardiovascular diseases, including atrial fibrillation (Van Wagoner et al., 1999) or
heart failure (Mukherjee and Spinale, 1998). Cyclic adenosine 3′,5′-monophosphate (cAMP) is
the main second messenger of the β-adrenergic receptor signaling inducing phosphorylation of
the LTCC and the ryanodine receptor to increase the amount of intracellular Ca2+ necessary for
heart contractility (responsible for positive chronotropic and inotropic effects during sympathetic
stimulation) (Guellich et al., 2014). Moreover, catecholamine stimulated β-adrenergic receptor
not only leads to cAMP effector dependent-troponin I phosphorylation to allow faster force
development and shortening during systole and faster force relaxation and re-lengthening during
diastole but also mediated cAMP effector dependent-phospholamban phosphorylation responsible
for Ca2+ re-uptake in the sarcoplasmic reticulum and myofilament relaxation (lusitropic effects)
(Bers, 2008). However sustained stimulation of this pathway may be detrimental thus leading to
cardiac remodeling and development of heart failure (Brodde, 1993; Kiuchi et al., 1993). Thus,
the proper physiological cardiac function relies on tight control of cellular cAMP concentration
by fine-tuning the balance between cAMP synthesis and degradation. In mammalian cells,
cAMP is produced by adenylyl cyclases (AC). Extracellular stimuli such as neurotransmitters,
hormones, chemokines, lipid mediators, and drugs, can modulate AC activity to increase or
decrease cAMP production by binding to a large number of transmembrane G protein-coupled
receptors (GPCRs). The degradation of cAMP to AMP is catalyzed by phosphodiesterases
(PDE) that are regulated by intracellular nucleotide concentrations, phosphorylation, binding
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of Ca2+/calmodulin and other regulatory proteins while cAMP
eﬄux out of the cell is mediated by cyclic nucleotide eﬄux
transporters. Over the years, several genetic models have
TABLE 1 | Cardiac phenotype for cAMP synthesis, hydrolysis and transporter proteins adapted from Guellich et al. (2014).
Class Protein
family
Substrate
affinity
Protein Cardiac function Available model References
AC AC1 Modulates If pacemaker current Mattick et al., 2007
AC5 Regulates contractility β-adrenergic dependent AC5 Knockout Iwamoto et al., 2003; Okumura
et al., 2003a,b; Tang et al., 2006
Myocardardial contractility increases LV
function increases heart rate, reduces inotropic,
lusitropic and chronotropic response to β1 AR
AC5 Transgenic Tepe et al., 1999; Esposito et al.,
2008; Lai et al., 2013
AC6 LV systolic and diastolic dysfunction
LV contractility increases with βAR stimulation
enhanced contractile function
AC6 Knockout
AC6 Transgenic
Gao et al., 1999, 2008; Phan
et al., 2007; Tang et al., 2008,
2010; Guellich et al., 2010
AC8 Enhances basal intrinsic contractility Cardiomyocyte specific AC8
Transgenic
Lipskaia et al., 2000
sAC Apoptosis of coronary endothelial cells heart
rate increase
ADCY10 knockout Kumar et al., 2009; M.G.
Informatics1
PDE PDE1 1–100µM PDE1A Cardiomyocyte hypertrophy
Cardiac fibroblast activation and cardiac fibrosis
Miller et al., 2011
PDE1B PDE1B Knockout Yu et al., 1997; M.G.
Informatics2
PDE1C PDE1C knockout mice Vandeput et al., 2007; M.G.
Informatics3
PDE2 30µM PDE2A PDE2 expression is increased in experimental
heart failure
L-type Ca2+ channel activity Contractility PDE2A: embryonic death (El7) Hartzell and Fischmeister, 1986;
Fischmeister et al., 2005
PDE3 0.08µM PDE3A Regulates β-adrenergic signaling, cardiac
contractility, pacemaking, and output reduces
cardiomyocyte apoptosis and prevents
ischemia/reperfusion induced myocardial
infarction cardiac contractility, LTCC activity
PDE3A knockout mice
Cardiomyocyte PDE3A
overexpressing mice
Tarpey et al., 2003; Ding et al.,
2005a,b; Sun et al., 2007;
Molenaar et al., 2013; Iwaya
et al., 2014
PDE4 1–4µM PDE4A ? PDE4A knockout mice Jin et al., 2005
PDE4B Arrhythmogenesis PDE4B knockout mice Leroy et al., 2011
PDE4D β-adrenergic signaling
RyR2 hyperphosphorylation, arrhythmia
PDE4D knockout mice Lehnart et al., 2005; Bruss et al.,
2008
PDE7 0.03–0.2µM PDE7A ? PD17A Knockout Yang et al., 2003
PDE8 0.04–0.8µM PDE8A Regulation of LTCC Ca2+ signaling, Ryr2 Ca2+
load
PDE8A knockout mice Patrucco et al., 2010
Cyclic nucleotide efflux transporter ABCC4 Enhances contractility and cardiac hypertrophy MRP4 Knockout mice Sassi et al., 2012
ABCC5 ?
This table summarized the main cardiac functions and available model for the different class of proteins regulating cAMP availability: references for ACs (AC1, Mattick et al., 2007; AC5
KO, Iwamoto et al., 2003; Okumura et al., 2003a,b; Tang et al., 2006; AC5 Tg, Tepe et al., 1999; Esposito et al., 2008; Lai et al., 2013; AC6 KO, Tang et al., 2008, 2010; AC6 Tg,
Gao et al., 1999, 2008; Phan et al., 2007; Guellich et al., 2010; AC8, Lipskaia et al., 2000; sAC, Kumar et al., 2009; M.G. Informatics), references for PDEs (PDE1A, Miller et al., 2011;
PDE1B, Yu et al., 1997; M.G. Informatics; PDE1C, Vandeput et al., 2007; M.G. Informatics; PDE2A, Hartzell and Fischmeister, 1986; Fischmeister et al., 2005; PDE3A, (Tarpey et al.,
2003; Ding et al., 2005a,b; Sun et al., 2007; Molenaar et al., 2013; Iwaya et al., 2014); PDE4A, Jin et al., 2005; PDE4B, Leroy et al., 2011; PDE4D, Lehnart et al., 2005; Bruss et al.,
2008; PDE7, Yang et al., 2003; PDE8, Patrucco et al., 2010) and references for cyclic nucleotide transporter (ABCC4, Sassi et al., 2012).
1http://www.informatics.jax.org/marker/MGI:2660854. Informatix JAX.
2http://www.informatics.jax.org/marker/MGI:97523. JAX.
3http://www.informatics.jax.org/reference/marker/MGI:108413. JAX.
been created to assess the role of the cAMP synthesis and
hydrolysis proteins in cardiac physiology (Table 1). Once cAMP
is produced it activates a set of diverse proteins, including
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cAMPdependent-protein kinase (PKA) or cAMP-dependent
exchange proteins (Epac), the two main cAMP effectors to
mediate downstream signaling as well as cyclic nucleotide-
gated ion channels (CNGC) and POPDC proteins (Beavo
and Brunton, 2002). From the compartmentation hypothesis
proposed by Brunton et al., in which cAMP microdomains
are distinctly coupled to cellular functions (Brunton et al.,
1981), a variety of technologies has been developed to study
in vivo the different localizations and organization around
macromolecular complexes to ensure a fine-tuned spatio-
temporal compartmentation of cAMP production (for detailed
reviews (Baillie, 2009; Edwards et al., 2012; Perera and Nikolaev,
2013). Recently, these tools led to the identification of a β2-
adrenergic-dependent cAMP compartmentation defect in failing
cardiomyocytes (Nikolaev et al., 2010). In this review, we will
focus on cAMP in synthesis and hydrolysis in cardiology, the way
to detect it and how to manipulate this cAMP pathway.
cAMP in the Cardiac Tissue
cAMP Synthesis
Adenylyl cyclases (AC) are ubiquitous enzymes that catalyze
the conversion of Adenosine triphosphate (ATP) into
cAMP and pyrophosphate. ACs structure consists in 12
transmembrane domains divided into 2 hydrophobics domains
(6 transmembrane domains each) and 2 main intracellular
loops called C1 and C2 that naturally dimerize to form the
catalytic domain (Figure 1A). In mammals, 9 transmembrane
and 1 soluble AC (sAC) encoded by different genes have
been identified and have different regulatory mechanisms
(Willoughby and Cooper, 2007). Mammalian ACs are strongly
activated by Mn2+ or Mg2+ (Tesmer et al., 1999) and inhibited
by millimolar concentrations of free Ca2+ probably acting as
a Mg2+ competitor (Mou et al., 2009) but at submicromolar
concentrations, Ca2+ can activate AC via calmodulin (CaM)
throught its binding to a putative helical structure on the C1b
region (Halls and Cooper, 2011).More precisely AC1, 3, and 8 are
Ca2+/CaM sensitive isoforms which localize in lipid rafts while
AC2, 4, 7, and 9 are Ca2+/CaM insensitive and are excluded
from these membrane domains (Willoughby and Cooper,
2007). On the contrary, biochemical studies on membrane
preparations revealed that AC5 and AC6 could be inhibited
by Ca2+ (independently of CaM) in the submicromolar range
(Guillou et al., 1999; Hu et al., 2002). Along with nitric oxide
(NO), Hydrogen sulfide (H2S) is a biological gaseous transmitter
able to modulate cAMP production. Using NO donors, the
gasotransmitter NO is thought to attenuate forskolin-stimulated
AC5 and AC6 isoforms activities without altering their basal
activity on membrane from rat striatum (Hudson et al., 2001).
Even if H2S is a poisonous gas used as a chemical reagent, H2S is
endogenously formed in mammalian cells from cysteine by the
action of cystathionine β-synthase with serine as a by-product
at a concentration around 50–160µmol/L (Goodwin et al.,
1989). In the central nervous system, H2S enhances NMDA
receptor-mediated response via cAMP production (Kimura,
2000) while in cardiac context it can also suppressed AC
activity and, therefore, decreased forskolin-stimulated cAMP
accumulation in different cell lines and tissue (Lim et al., 2008;
Yong et al., 2008). In the cardiomyocytes, expression of AC1,
AC5, AC6, AC8, and sAC has been detected and most function
as modulators of inotropic and chronotropic β-adrenergic
receptor (β-AR) signaling output (Table 1) but AC5 and AC6
represent the dominant isoform (Defer et al., 2000). Along with
AC distribution within membrane microdomains (Efendiev
and Dessauer, 2011), cAMP synthesis is spatially restricted by
localization of activating receptors like β1-adrenergic receptors
or β2-adrenergic receptors at caveolae or non-caveolae plasma
membrane domains (Rybin et al., 2000; Ostrom et al., 2001).
FIGURE 1 | Schematic structure of ACs and PDEs. (A) Structure of Adenylyl cyclase is comprised of 2 transmembrane domains (M1 and M2 6 helixes each) and
2 cytosolic domains (C1 and C2) subdivided into a and b domains. C1 and C2 contain the catalytic core, the Gα and the forskolin binding sites and other regulatory
sites. C2b domain is almost inexistent in all AC isoforms. (B) PDEs are homodimers with the exception of PDE1 and PDE6 (usually heterotetramers). PDEs have an
NH2-terminal regulatory domain and share a conserved catalytic domain located in the COOH-terminal portion of the protein. The structure of the regulatory domain
varies according the PDE isoform. GAF is an acronym for cGMP-specific PDE, Adenylyl cyclases and FhlA, NHR for N-terminal Hydrophobic Region, PAS for
Per-ARNT-Sim and Calm. BD for calmodulin binding domain. No known domains are present in PDE7 or PDE9 regulatory C-terminal part. PDE4 proteins are classified
as “long” or “short” isoforms, depending on the presence or absence of two highly conserved domains, Upstream Conserved Region 1 (UCR 1) and Upstream
Conserved Region 2 (UCR 2) which interact to form a regulatory module that may influence catalytic activity by a PKA-dependent phosphorylation mechanism
(Houslay, 2001; MacKenzie et al., 2002).
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Moreover, specific A-kinase anchor proteins (AKAP) complexes
(Kapiloff et al., 2014) have been identified as a potential molecular
mechanism for the formation of specific cAMP microdomains
(Kapiloff et al., 2014). The AKAPs constitute signaling hub
proteins that scaffold on a same membrane domain the AC and
the regulatory subunit of protein kinase A (PKA) cAMP effector,
thus confining the enzyme activity to discrete locations within
the cell. Cardiac myocytes exhibit at least four distinct AKAP
complexes: AKAP79/150 (aka AKAP5) with AC5/6 (Nichols
et al., 2010); mAKAPβ (aka AKAP6) with AC2/5 (Kapiloff et al.,
2009), YOTIAO (aka AKAP9) with AC2/9 (Piggott et al., 2008),
and AKAP18δ with PKA (Fraser et al., 1998) (Figure 2).
cAMP Elimination: Phosphodiesterases and
Cyclic Nucleotide Efflux Transporters
Phosphodiesterases
Cyclic AMP is hydrolyzed exclusively by cyclic nucleotide PDEs
classified in 11 families and encoded by at least 21 different
genes with the existence of some splice variants (Omori and
Kotera, 2007). PDEs are structured around a catalytic domain
containing the cyclic nucleotide binding site conserved across
all families and a regulatory N-terminus varying according to
the different PDEs (Figure 1B). In the heart, 8 PDE families
have been described: PDE1; PDE2, PDE3, PDE4, PDE5, PDE7,
PDE8, and PDE9. Among them, PDE1, PDE2, and PDE3 are
dual-specificity enzymes that can hydrolyze both cAMP and
cGMP while PDE4, PDE7, PDE8 selectively hydrolyze cAMP
and conversely PDE5, PDE9 selectively hydrolyze cGMP. Of the
cAMP-hydrolyzing PDEs expressed in the heart, cGMP inhibits
PDE3 and possibly PDE1, whereas PDE2 is activated by cGMP
(detailed review in Zaccolo and Movsesian, 2007). Jurevicius
and Fischmeister (1996a,b) provided the first direct evidence
for PDE-mediated cAMP signaling compartmentation, showing
that PDE inhibition allowed local β-adrenergic stimulation to
enhance Ca2+ currents in frog ventricular myocytes (Jurevicius
and Fischmeister, 1996a,b). Later on, imaging approaches
confirmed that PDEs play a key role in shaping the intracellular
cAMP gradient in rat neonatal cardiomyocytes (Zaccolo et al.,
2000; Zaccolo and Pozzan, 2002). Like ACs, PDEs have also been
shown to be compartmented by AKAPs complexes. Thus, specific
cAMP hydrolysis-based PDE4 enzyme were shown to interact
with mAKAP for PDE4D3 (Dodge et al., 2001); AKAP9 for
PDE4D3 (Taskén et al., 2001), AKAP95 (aka AKAP8) for PDE4A
(Asirvatham et al., 2004), AKAP149 for PDE4A (Asirvatham
et al., 2004) (Figure 2).
Cyclic Nucleotide Efflux Transporters
In addition to PDEs and ACs, the intracellular concentration
of cAMP is regulated by its eﬄux into the extracellular space
through a specific transmembrane transport system named
multidrug resistance proteins (MRP) (Cheepala et al., 2013)
that belongs to the ATP-binding cassette (ABC) transporter
FIGURE 2 | AKAP-dependent AC and PDE compartmentalizations in the cardiomyocyte. Abbreviations stand for: AKAP, A-kinase anchor proteins; PKA,
Protein Kinase A; β2AR/β1AR, beta adrenergic receptor; PLN, Phospholamban; EPAC, cAMP-dependent exchange proteins; AC, Adenylyl cyclase; RyR, Ryanodine
Receptor; SERCA, sarco/endoplasmic reticulum Ca2+-ATPase; KCNQ1, potassium channel voltage gated KQT-like subfamily Q; PDE, Phosphodiesterase; T-tubule,
Transverse tubule; LTCC, L-type calcium channel.
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superfamily (subfamily C). Three of them (MRP4 aka ABCC4,
MRP5 aka ABCC5, and MRP8 aka ABCC11) have the ability
to actively extrude cAMP and cGMP from the cell (Kruh
and Belinsky, 2003) and in cardiac myocytes, MRP4 has been
shown to enhance cAMP formation, contractility, and cardiac
hypertrophy (Sassi et al., 2012). The compartimentation of
MRPs expression may also play an important role in the
intra- and extracellular cAMP signaling processes. For instance,
caveolin-rich membrane MRP4 localization (Sassi et al., 2008)
could explain the local MRP4-modulated contraction of cardiac
myocytes induced by activation of β-adrenoceptor (Sellers et al.,
2012).
cAMP in Heart Failure
Heart failure (HF) occurs when the heart is unable to pump
sufficiently to maintain blood flow to meet the body’s needs.
Around 2% of adults have HF and this percentage increases to 6–
10% for people over the age of 65 (McMurray and Pfeffer, 2005).
The HF syndrome arises as a consequence of an abnormality
in cardiac structure, function, rhythm, or conduction. As stated
in introduction, cAMP primarily, but not exclusively, controls
beating frequency, force of contraction and relaxation, essentially
through the β-adrenergic signaling pathway. This pathway is
necessary for the beneficial effects of catecholamines on cardiac
contractility. During heart failure set up, increased sympathetic
activity drives the βAR overstimulation in cardiomyocytes, thus
promoting higher intracellular cAMP signals for compensatory
cardiac function in the heart (Baker, 2014). However, chronic
βAR stimulation and uncontrolled cellular cAMP signals have
been shown to affect heart function in a much more detrimental
way responses such as cell apoptosis (Zhu et al., 2003) and
the loss of pump function (Michel et al., 1990; Engelhardt
et al., 1999; Lohse et al., 2003), ultimately leading to HF
setup. During the ongoing of the disease, a down-regulation
of β1AR expression (Nikolaev et al., 2010) is correlated with
a modulation of Gαi proteins (Eschenhagen et al., 1992a,b)
expression to attenuate cAMP synthesis. The ratio between
β1AR and β2AR converts the latter to be the major βAR
subtype in failing hearts. Interestingly, associated with this
receptor expression imbalance, the β2AR dominant-induced
cAMP signal is broadly distributed in the failing heart (Nikolaev
et al., 2010) compare to a compartmentalized cAMP signal in
physiological condition. The functional output of this broadly
distributed cAMP signal in modulating contractile properties
in failing hearts has to be studied. In failing cardiomyocytes,
chronic β2AR stimulation also promotes CaMKII-dependent
contractile responses which has a pronounced role in promoting
the development of cardiac hypertrophy, myocyte apoptosis,
cardiac dysfunction and arrhythmias by causing sarcoplasmic
reticulum Ca2+ overload (Anderson et al., 2011). Inhibition of
CaMKII is able to ameliorate cardiac remodeling and reduce
cardiac arrhythmias after myocardial infarction (Zhang et al.,
2005). Although the direct link between cAMP and CaMKII is
still missing, the detrimental CaMKII activity in cardiomyocytes
could be related to dysregulation of distribution of cAMP
signals under chronic βAR stimulation. HF is a complex process
where the various components in the cAMP signaling pathway
constitute potential pharmacological targets.
Modulation of cAMP Concentration in the
Cardiac Tissue
Modulation of cAMP Production
Targeting Adenylyl Cyclases
Pharmacological AC activators
The most prominent AC activator is forskolin (FSK). FSK, a
diterpene extracted from the plant Coleus forskohlii, directly
activates all AC isoforms except AC9. Despite a strong
hydrophobic property, its action is not limited to the native
membrane-bound form of the enzyme since it can readily
stimulate some synthetic soluble ACs. FSK binds to the same cleft
that contains the active site of AC (Tesmer et al., 1997) where
it glues together its two cytoplasmic domains (Figure 1A) by a
combination of hydrophobic and hydrogen-binding interactions
(Zhang et al., 1997). Based on equilibrium dialysis experiments
of the C1 and C2 domains of type AC5 and AC2, respectively,
the C1/C2 complex binds only one Gsα, one ATP, and one FSK
molecule (Dessauer et al., 1997). However, FSK has been shown
to also inhibit a number of membrane transport proteins and
channel proteins like Glucose transporter or voltage dependent
K+ channel (Laurenza et al., 1989). As Protein kinase C (PKC)
activates AC2 by phosphorylating it on Thr-1057 (Böl et al.,
1997), another alternative, but more restrictive one to activate
AC, relies on the use of Phorbol 12-myristate 13-acetate (PMA) a
phorbol diester and a potent tumor promoter known to activate
PKC signaling. Thus, PKC-dependent phosphorylation of AC-C1
domain induces AC activation (Ebina et al., 1997). However, one
must be cautious on the use of PMA as a specific AC-activator
since PMA has also been reported to have actions on non-kinase
proteins including chimaerins, RasGRP, and Unc-13/Munc-13
(Han and Meier, 2009; Kazanietz et al., 1995).
Pharmacological AC inhibitors
As schemed in Figure 1A, ACs are structured around 2
hydrophobic domains and 2 main intracellular loops containing
the catalytical domain and the diterpene regulatory site. Based
on this structure, ACs inhibitors can be divided into 4 groups
(reviewed in Seifert et al., 2012): (i) the inhibitors competing
with the ATP at the catalytic site like MANT-GTP (Gille
and Seifert, 2003), (ii) the uncompetitive P-site inhibitors like
2′,5′-dideoxyadenosine-3′-tetraphosphate Vidarabine [aka 9-β-
D-arabinofuranosyladenine (ara-A)] (Seifert, 2014) or NKY80
(a cell-permeable quinazolinone) to name a few, which work
by stabilizing a pyrophosphate-bound transition state (Dessauer
et al., 1999; Onda et al., 2001), (iii) the allosteric non-competitive
inhibitors targeting the diterpene regulatory site like BODIPY-
FS in presence of divalent cations (Erdorf et al., 2011), and
(iv) the allosteric non-competitive inhibitors targeting alternated
and unknown site like calmidazolium (Haunsø et al., 2003).
Even though some specificity has been assigned to some of the
molecules listed, to our knowledge, those inhibitors have not
been accurately examined at all ACs isoforms, thus preventing
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any formal conclusion only based on their use to assess the
involvement of AC activity.
Targeting G-protein Coupled Receptor Signaling
We previously mentioned that cAMP constitutes the master
second messenger of β-adrenergic receptor signaling which
belong to the G protein-coupled receptors (GPCRs) family.
According to conventional knowledge, 7 transmembrane GPCRs
at the plasma membrane convert extracellular signals into
intracellular ones through canonical heterotrimeric G proteins
which transduce signals from GPCRs to secondary effectors
thus leading to the second messengers production and the
propagation of the signal through ensuing regulation of
numerous downstream intracellular signaling targets (Gilman,
1987). G proteins localized on the cytoplasmic side of the plasma
membrane and are composed of a guanine nucleotide binding
α subunit (Gα) and a βγ dimer (Gβγ), both constitutively
associated in the G protein inactive state. Upon GPCR activation,
the Gαβγ protein associates with the receptor thus allowing
GDP/GTP exchange on the Gα GTPase domain, leading to
subsequent Gα-GTP and Gβγ dissociation both regulating
downstream specific signaling targets (Denis et al., 2012).
Intrinsic GTPase activity of the Gα then allows GTP hydrolysis
and to turn off the G protein activity to its initial inactive
Gαβγ associated state. G proteins have been classified into
five subfamilies (Gi/o, Gs, Gq/11, and G12/13) according to
the secondary effector of the Gα subunit (Denis et al., 2012).
Thus, isoforms of the Gαi/o family classically inhibit ACs and
cAMP production while, conversely, isoforms from the Gαs
family activate ACs to favor cAMP production. It follows that
modulation of the activity of cardiac expressed Gαi- or Gαs-
coupled receptors either through the use of selective GPCR
agonists and antagonists or G proteins activators or inhibitors
will directly alter the G protein activity and cAMP availability.
GPCR agonists and antagonists
In the human genome, it is estimated that the GPCR superfamily
consists in ∼600–1000 receptors (Lander et al., 2001; Vassilatis
et al., 2003; Fredriksson and Schioth, 2005) where ≈ 200 have
known cognate agonists and the larger part are still “orphan,” i.e.,
without yet identified agonists (Vassilatis et al., 2003). Evaluation
of GPCR expression in vivo has been largely hampered by
lack of specific antibodies against this class of receptors. Thus,
over the years, microarray technology allowed researchers to
monitor the mRNA expression levels of thousands of GPCRs
encoding genes. Based on the available genomic data (Hakak
et al., 2003; Katugampola and Davenport, 2003; Tang and
Insel, 2004; Regard et al., 2008; Moore-Morris et al., 2009), we
tried to summarize the different GPCRs detected in the whole
cardiac tissue (cardiomyocytes, endothelial cells, fibroblasts. . . )
(Table 2), their classical G protein coupling and a selective
agonist/antagonist for most of them. This list is non-exhaustive
and selectivity or description of these compounds will not be
detailed here. Thus, selective pharmacological targeting of Gαi-
or Gαs-coupled cardiac receptors represents a way to modulate
intracellular cAMP levels. It is noteworthy that the classical
GPCR coupling has to be enlarged as a recent study shows
dual agonist occupancy of the AT1-R and α2C-AR heterodimer,
two GPCRs known to be coupled to Gαq and Gαi, respectively,
created an original conformation different from the active
individual protomers and triggered an atypical Gs/cAMP/PKA
signaling (Bellot et al., 2015). Thus, co-stimulation or bivalent
ligand development might be a new pharmacological area to
regulate cAMP signaling (Berque-Bestel et al., 2008; Lezoualc’h
et al., 2009).
Gα activators
Cholera toxin (CTX) is a specific Gαs potent activator secreted by
the bacteriaVibrio choleraewhich catalyzed the ADP-ribosylation
of the Gαs proteins. The ADP-ribosylation blocks the Gαs
catalytic activity and thus prevents the Gαs subunit to hydrolyze
the GTP once activated, leading to the ensuing sustained Gs
and AC activity (De Haan and Hirst, 2004). CTX administration
in non-ischemic or ischemic heart contributes to the genesis
of arrhythmia highlighting the essential role for Gαs in the
regulation of cardiac physiology (Huang and Wong, 1989).
More recently, Pasteurella multocida toxin (PMT), produced
by toxigenic strains of the Gram-negative Pasteurella multocida
bacteria, was identified as a potent and selective activator of
Gαq, Gαi, and Gα13 by deamidating a glutamine residue in the
switch II region of the Gα-GTPase domain (Orth et al., 2005,
2008). It was recently shown that, in vivo, PMT treatment in
mice increased secretion and expression of connective tissue
growth factor (CTGF) in cardiac fibroblasts to aggravate cardiac
hypertrophy and fibrosis (Weise et al., 2015).
Gα inhibitors
Basically, all Gα subunits inhibitors share a common molecular
mechanism by preventing the GDP/GTP exchange on the Gα-
GTPase domain. A famous specific and highly effective Gαi
inhibitor is Pertussis Toxin (PTX). PTX is a protein complex
released by the bacterium Bordetella pertussis in an inactive form.
PTX catalyzes the ADP-ribosylation of the Gαi subunit of the
heterotrimeric G protein. The Gαi subunit remains locked in
its GDP-bound inactive state, thus unable to interact with the
receptor and to inhibit adenylyl cyclase activity (Hsia et al.,
1984; Burns, 1988). PTX-pretreatment is classically used to
delineate the involvement of Gαi-dependent signaling. It revealed
for instance an increase in β-AR dependent inotropic response
and cAMP accumulation in isolated ventricular cardiomyocytes
(Melsom et al., 2014), confirming the dual coupling of β2-AR
to both Gαi and Gαs (Xiao, 2001) in the cardiac tissue. On
a purified Gα activity assay, suramin, an antimicrobial drug,
was identified as a more selective inhibitor for Gαs (IC50 ≈
250 nM) than for Gαo (IC50 ≈ 2µM) or Gαi (IC50 ≈ 5µM).
Suramin exerts its effects by binding the effectors binding site
on the Gα proteins (Freissmuth et al., 1996). It has to be noted
that suramin is a large highly sulfonated and negatively charged
molecule that limits its use to in vitro studies as it cannot
cross the cell plasma membrane. Hohenegger and coworkers
worked on suramin derivatives to increase specificity toward
Gαs and identified two compounds (NF449 and NF503) that
suppress the Gαs activation coupled to β-adrenergic receptors,
whereas they affect the Gαi/Gαo- and Gαq-coupled receptors
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TABLE 2 | GPCR expressed in heart: Gα coupling and pharmacological way to modulate their signaling.
Receptor Subtype Coupling Example of agonist Antagonist
α-Adrenergic la, lb, 1D, Gq Phenylephrine, Methoxamine Corynanthiane, Prazosin
2a, 2c Gi UK14304, B-HT92O Yohimbine, RX821002
β-adrenergic β1, β2, β3 Gs, Gi Isoproterenol Alprenolol, Pindolol, Propranolol
Adenosine Adoral, Gi CHA, CPA CPX, CPT, N-0840
2a,2b Gs CGS21680, DPMA, HENECA KW6002, Alloxazine, SCH-58261
Adrenomodulin CGRP Gi, Gs
Angiotensin AT1a Gq, Gi AngII, AngIII L162313 Losartan, Candesartan
AT2 Gi AngII, AngIII CGP42112A PD123319, L-159686
Apelin APJ Gi Apelin13
AVPR1a Gq vasopressin Relcovaptan
Bradykinin Bdkrbl, 2 Gq Lys-BK B9430
Calcium sensing Ca-SR Gs
Cannabinoid CB1 Gi THC, CP-5594O, Nabilone SR141716A, AM25l
Chemokine receptor CX3CR1, Gi Fractalkine
CXCR2 Cri IL-8, GCP2
CXCR4,7 Gi SDF1α AMD3100
CXCR6 Gi CXCL16
CCBP2, Gi
CCR1, 5 Gi MIP1α
CCR2 Gi MCP-1
CCR10 Gi CTACK
XCR1 Gi xCL1
Complement component receptor C3aRl, C5R1 Gi
Corticotropin releasing hormone CRHR2 Gs CRF, UCN1 Astressin
Cysteinyl leukotriene Cystl1 Gq LTD4 Cinalukast
Dopamine Drd2 Gi U-91356A, TNPA L-741626
Drd3 Gi PD128907, BP897 Nafadotride, GR103691
Endothelin ET-A, ET-B Gq ET1 PD142893
Frizzled Fzdl, 2, 3, 5, 6, 7, 8
Galanin GalR2 Gq Galanin, GALP Galantide
GLP1 Gs
Glucagon Gq, Gs
Gonadotropin receptor LGR6, 7 Gi, Gq
GPCR5 Raig2, GPCR5c ?
Growth hormone
secretagogue-receptor
GHS-R1a GS, Gq
Histamine H1 Gq Pyrilamine
H2 Gs Amthamine Cimetidine
H3 Gi Immethridine Ciproxifan
Latrophilin Lphn1, 2 011-15 alpha-Latrotoxin
Mas Mas1, GPR168 ?
Melanin concentrating hormone SLC-1 ? MCH SNAP794l
Melanocortin MC3R Gs γ2-MSH SHU9119
Melatonin MT1 Gi, Gq Melatonin, S20098 Luzindole
MT2 Gi Melatonin, S20098 Luzindole
Muscarinic M2, M3 Gi, Gq Bethanecol, Xanomeline, Metoclopramine Gallamine, Atropine, Scopolamine
Neuromedin U NMUl, NMU2 Gi, Gq NMU
Neuropeptide Y receptor NPY1, 2 Gi NPY BIBP3226, BIIE0246
Nucleotide P2Y1 Gq 2MeSADP BzATP, Suramin
P2Y2 Gq, Gi UTPγs Suramin
P2Y4 Gq, Gi UTP ATP
(Continued)
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TABLE 2 | Continued
Receptor Subtype Coupling Example of agonist Antagonist
P2Y5 Gi, G12/13
P2Y6 Gq UDP Suramin
P2Y11 Gq, Gs BzATP Suramin
P2Y13 Gi 2MeSADP Ap4A
P2Y14 Gi UDP-glucose
Opioid MOP Gi DAMGO Cyprodime
DOP Gi DPDPE Naltrindole
KOP Gi Enadoline GNTI
Opsin Opn4 Gi, Gq
Oxytocin OXTR Gq Oxytocin, Carbetocin
P518RF amide SP9155 ? P518
Vasoactive Intestinal Peptide receptor VIPR2 Gs, Gq VIP acetyl-His-PheLysArg-VIP-GRF
PAR PAR1 Gi, Gq,
G12/13
Thrombin, Trypsin BMS200261
PAR2 Gi, Gq Trypsin
PAR4 Gq Thrombin, Trypsin t-cinnamoylYPGKF
Platelet-activating factor receptor PTAFR Gq PAF Israpafant
Prolactin releasing peptide GR3
Prostacyclin Ptgir Gs
Prostanoid EP1 Gq Iloprost SH-19220
EP4 Gs ONO-AE1-734 AH23848
Relaxin-H2 LGR7, Rxfp4 Gi
Serotonin 5HTR1a Gi R(+)-8-OH-DPAT Spiperone
5HTR1b Gi Sumatriptan, CGS12066 GR55562, SB216641
5HTR2b Gq BW723C86 YM348
5HT4 Gs BIMU8 GR113808
Smoothened Smoh Gi
Somatostain SSTR3 Gi L-796778 NVP-ACQ090
SSTR4 Gi NNC26-9100 s
Sphingosine Edg1 Gi S1P, FTY720-P VPC23019
Edg5 Gq,Gi G12/13 S1P JTE-013
Edg3 Gq, Gi,
G12/13
S1P, FTY720-P VPC23019
LPA Edg2 Gi, G12 13 1-oleyl-LPA VPC32183
Substance P NK-1 Gq substance P GR-82334
Thromboxan Tbxa2r Gq Thromboxan Seratrodast
Urotensin GPR14 Gq UII [Cha6]U-II(4-11)
Other GPCR expressed in Heart
CD97 GPR77(C5L2)
ELTD1 GPR82
EMR1 GPR107
TM7SF3 GPR108
GPR1 GPR116
GPR10 GPR120
GPR17 GPR124
GPR2l GPR125
GPR22 GPR133
GPR27 GPR135
GPR30 GPR137
GPR31 GPR137b
(Continued)
Frontiers in Pharmacology | www.frontiersin.org 8 October 2015 | Volume 6 | Article 203
Boularan and Gales Modulating and measuring cardiac cAMP
TABLE 2 | Continued
Other GPCR expressed in Heart
GPR34 GPR146
GPR4 GPR153
GPR44 GPR161
GPR48 GPR175
GPR54 GPR182
GPR56 GPR183 (Ebi2)
This table summarized the list of mRNA encoding for GPCRs detected in the whole cardiac tissue (cardiomyocytes, endothelial cells, fibroblasts…) extracted from (Hakak et al., 2003;
Katugampola and Davenport, 2003; Tang and Insel, 2004; Regard et al., 2008; Moore-Morris et al., 2009), the main known Gα protein coupling, an example of an agonist and an
antagonist (this list is non-exhaustive and selectivity for each molecule is not discussed).
(A1-adenosine and angiotensin II receptor, respectively) to a
much lesser extent (Hohenegger et al., 1998). Lately, BIM-46174
and BIM-46187 were classified and used as pan Gα inhibitors
targeting Gαs, Gαq/11, Gαi/o, and Gα12/13 family (Prévost et al.,
2006). However, these cell permeable compounds have not be
tested toward all the individual members of Gα subunit family
andmore recently Kostenis and colleagues found that BIM-46187
was more selective to inhibit Gαq depending on the cellular
context (Schmitz et al., 2014).
Gβγ complex inhibitors
Smrcka and coworkers described small molecule Gβγ inhibitors
that selectively block Gβγ-binding interactions to their effectors,
including M119 and its highly related analog, gallein (Lehmann
et al., 2008). These compounds blocked interaction of Gβγ
and GRK2 in vitro and reduced β-AR–mediated membrane
recruitment of GRK2 in isolated adult mouse cardiomyocytes
(Casey et al., 2010). The authors showed M119 enhanced both
adenylyl cyclase activity and cardiomyocyte contractility in
response to β-AR agonist (Casey et al., 2010). More recently,
in a screen for the identification of OXE receptor antagonists,
Gue1654 was discovered as a biased inhibitor that selectively
prevent Gβγ signaling without affecting the Gα pathway
(Blättermann et al., 2012). The molecular mechanism underlying
Gue1654 action is still under investigation.
Targeting Tyrosine Kinase Receptor Signaling
It has to be noted that AC have been involved in the mechanisms
of action of insulin and other peptides of the insulin superfamily
like Insulin-like Growth factor I, relaxin and mollusc insulin-like
peptide which are ligands for tyrosine kinase receptors (TKR)
(Pertseva et al., 2003). Earlier, it was shown that in the heart
EGF, another TKR, triggered some AC mediated effect (Nair and
Patel, 1993). At a molecular level, TKR dependent activation of
AC can rely on the activation of PI3K, PKCζ, or the Gβγ complex
(Wilson et al., 1996; Standaert et al., 1997; Molina-Munoz et al.,
2006). Thus, modulating activities of TKRs and their signaling
regulators constitute an alternative approach to modulate cAMP
but such compounds will not be described in this review.
Modulation of cAMP Degradation
Phosphodiesterases Inhibitors
The cardiostimulatory action of PDE make their inhibition
as a promising therapeutic approach for the treatment of
heart failure by sustaining cAMP production and action.
Methylated xanthines, like theophylline, caffeine, or Iso-butyl-
methyl-xanthyl (IBMX), are long known to act as competitive
nonselective PDE inhibitors (Hess et al., 1975) but they
also exhibit nonselective PDE action like adenosine receptor
antagonist activities (Ukena et al., 1986). Over the years, several
more specific and selective PDEs inhibitors have been developed.
Representative selective inhibitors that can be used in cardiac
tissue are listed below. Originally, 8-MM-IBMX was thought to
be PDE1 selective (Rybalkin et al., 2002), but an extensive in vitro
study characterized more potent and more selective compounds
able to inhibit PDE1 activity like SCH51866 (Dunkern and
Hatzelmann, 2007). The first specific inhibitor developed for
PDE2 was EHNA [erythro-9-(2-hydroxy-3-nonyl)adenine] with
an IC50 value of ∼1µM (Podzuweit et al., 1993) but a screen
of compounds developed by Bayer showed that BAY60-7550
(an EHNA analog) was 100-fold more potent and 50-fold more
selective for PDE2A over other PDEs compared to EHNA
(Boess et al., 2004). Cilostamide-dependent PDE inhibition was
discovered in 1970’s (Hidaka et al., 1979) but cilostamide and its
derivative selectivity for PDE3 family was described by Sudo et al.
(2000). The prototypical PDE4 inhibitor is rolipram; originally
named ZK62711, that was discovered in 1976 (Schwabe et al.,
1976) but its use was limited by its associated side effects,
particularly those affecting the gastrointestinal tract (Barnette
and Underwood, 2000). Thus, in 2010, potency and selectivity
of roflumilast and its active metabolite have been studied for
all PDE (Hatzelmann et al., 2010). Roflumilast does not affect
PDE enzymes apart from PDE4 family, and has a subnanomolar
inhibitor activity toward all PDE4 splicing variants tested (Rabe,
2011). As the PDE4 family is encoded by 4 genes (PDE4A,
B, C, or D) and 27 splice variants, identification of selective
PDE4 subtypes inhibitors has been boosted and especially for
PDE4B that can be selectively inhibited for example by triazine
derivative (Hagen et al., 2014). ASB16165 was characterized
as a specific and highly potent inhibitor for PDE7A with an
IC50 value of 15 nM for human PDE7A (Kadoshima-Yamaoka
et al., 2009). PDE8s are inhibited by dipyridamole, despite
this drug is also known as a relatively nonselective cGMP
specific PDE5 inhibitor (Soderling et al., 1998) while two studies
have described a newly available PDE8 inhibitor developed by
Pfizer, PF-04957325 (Vang et al., 2010; Shimizu-Albergine et al.,
2012).
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Cyclic Nucleotide Efflux Transporters: Description
and Inhibitors
As mentioned earlier, ABCC [ATP-binding cassette (ABC)
transporter superfamily (subfamily C)] regulates cAMP eﬄux
into the extracellular space to decrease cAMP availability. Three
of them (ABCC4, ABCC5, and ABCC11) are expressed in cardiac
tissue but ABCC4 is the most studied and has been shown to
enhance cAMP formation, contractility, and cardiac hypertrophy
(Sassi et al., 2012). Non selective inhibitors including MK-571,
dipyrimamole or indomethacin (Reid et al., 2003) have been
described to dually inhibit ABCC transporters and PDEs (Xie
et al., 2011). Thus, the interpretation of experiments using those
compounds has to take in account their side activities. In 2014,
a high throughput screening identified Ceefourin 1 and 2 as
highly selective ABCC4 inhibitors (Cheung et al., 2014). The
authors described a micromolar inhibition of ABCC4 over other
members of ABCC transporter families but no data are available
concerning their effect on PDE activity (Cheung et al., 2014).
Optogenetics Methods to Modulate cAMP
Availability
The genome of Beggiatoa, a sulfide-oxidizing bacterium, revealed
the presence of a DNA sequence encoding for a cytosolic adenylyl
cyclase directly linked to a BLUF (blue light receptor using
FAD) type light sensor domain. This photoactivatatable adenylyl
cyclase (bPAC) shows a low cyclase activity in the dark but
that increases about 300-fold upon light activation (Stierl et al.,
2011). Efetova et al. pioneered the use of bPAC to distinguish
between the functions of alternative cAMP effectors in the in vivo
regulation of a Drosophila melanogaster physiological process
(Efetova et al., 2013) while Von Zastrow’s group recently used
the bPAC fused to different targeting sequences to assess the
role of cAMP compartmentation in GPCR signaling (Tsvetanova
and von Zastrow, 2014). Recently, a red light-activated PDE
was engineered by recombining the photosensor module of
Deinococcus radiodurans bacterial phytochrome with the effector
module of Homo sapiens PDE2A (Gasser et al., 2014). Compare
to the bPAC system, the red-shifted activation of this new tool
will allow the creation of interesting animal model to study
the spatio-temporal cAMP signaling pathway. This concept was
declined for multiple targets referenced and collected by the
CHROMus project (Shui et al., 2014) and applied to GPCRwhere
the cytosolic part of the Rhodopsin receptor was replaced by
the β2-AR receptor part to create a photoactivable Gαs coupled
GPCR (Airan et al., 2009).
Modulation of cAMP Effectors
cAMP has four direct intracellular targets: protein kinase A
(PKA), the exchange protein activated by cAMP (EPAC), the
cyclic nucleotide gated ion channels (CNGC) and the popeye
domain containing protein (POPDC). cAMP output signaling
can be modulated by targeting its effectors.
PKA Inhibitors and Activators
Inactive PKA relies on an heterotretamer consisting of two
regulatory (R) and two catalytic (C) subunits (Figure 3A). Two
principal isoforms of the R-subunit (type I and II) each further
subclassified into α and β subtypes (Hofmann et al., 1975) and
three isoforms of the C-subunit have been described in mammals
(Cα, Cβ, and Cγ) (Uhler et al., 1986; Beebe et al., 1990). RIIα is the
major isoform expressed in the heart but can also be found in the
brain (Skalhegg and Tasken, 2000). RIα is also expressed in the
cardiac tissue and the central nervous system while RIβ and RIIβ
are respectively found in the spinal cord or brain and liver or fat
tissue (reviewed in Skalhegg and Tasken, 2000). In regard to its
molecular mechanism of activation, two cAMP molecules bind
to each R-subunit and induce a conformational rearrangement of
PKA which initiates the functional dissociation of the regulatory
from the catalytic subunits (Murray, 2008).
The classically used PKA inhibitors, H89 (isoquinolone
derivative) and KT5720 (synthesized from fungus Nocardiopsis
sp.) act as competitive antagonists of the cAMP nucleotide for
the binding site on the PKA regulatory subunit (Kase et al., 1987;
Engh et al., 1996). Studying the specificity for commonly used
inhibitors for a range of protein kinases, Davies and coworkers
found unspecific effect for H89 and KT5720 as they were found
to inhibit other kinases at lower concentrations than those used
to prevent PKA activation (Davies et al., 2000). For instance,
H89 is able to inhibit ROCK, S6K, PKBα, or MSK1 while
KT5720 inhibits PDK1 and PHK (Davies et al., 2000). Alternate
PKA inhibitors were developed including Rp-cAMPs and its
derivatives. Those inhibitors act as competitive antagonists of the
cyclic nucleotide binding domain on the regulatory PKA subunit.
A study in Dictyostelium has characterized both selectivity and
degradation of such compounds (Schaap et al., 1993) and
demonstrated that those molecules can indeed inhibit proteins
containing other cAMP binding domain. Finally, the protein
kinase inhibitor peptide (PKI) remains likely the most specific
way to interfere with PKA as it binds to the free catalytic
subunit and prevents phosphorylation of PKA targets (Dalton
and Dewey, 2006). However, high concentration of this peptide
can also inhibit PKG signaling (Glass et al., 1992). By opposition
to PKA inhibitors, 8pcpt-cAMP and its derivative (Sp-5,6-DCl-
cBiMPS) are cell permeable cAMP analogs that can bind the
PKA-cAMP binding site and promote the activation of PKA
downstream effectors (Sandberg et al., 1991).
Epac Inhibitors and Activators
Epac (exchange protein activated by cAMP) constitutes with PKA
the main direct cAMP effector and has been identified by two
independent group in 1998 (de Rooij et al., 1998; Kawasaki et al.,
1998). In mammals, two isoforms of Epac (Epac1 and Epac2),
products of independent genes have been identified which
contain a cAMP binding domain (that is homologous to that
of PKA R subunits) and other conserved domains (Figure 3B).
Its activation relies on a conformational rearrangement of the
protein promoted by cAMP binding. Epac1 is mostly abundant
in the heart, kidney, blood vessels, adipose tissue, central nervous
system, ovary, and uterus, whereas Epac2 splice variants (Epac2A
and Epac2B) are mostly expressed in the central nervous system
(Epac2A), adrenal gland (Epac2B), and pancreas (Epac2A) (de
Rooij et al., 1998; Kawasaki et al., 1998; Niimura et al., 2009).
Once activated, Epac proteins activate the Ras superfamily
small G proteins Rap1 and Rap2 (for review Cheng et al.,
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FIGURE 3 | Schematic structure of PKA and EPAC. (A) The catalytic (c) subunit of cAMP-dependent Protein Kinase (PKA) is a serine/threonine protein kinase
associated, in the absence of cAMP, with the regulatory (R) subunit to form the inactive PKA holoenzyme. cAMP can bind to A or B sites in the regulatory subunits and
induces the dissociation of the catalytic subunits. (B) Epac structure showing the conserved cAMP binding domain (CBD), Disheveled/Egl-10/pleckstrin (DEP)
domain, RAS exchange motif (REM) domain, RAS association (RA) domain, and CDC25-homology domain (CDC25HD).
2008) by functioning as guanine nucleotide exchange factors. In
cardiomyocytes, Epac proteins are involved in the formation of
gap junctions to coordinate cardiac contractions through gating
ions and small molecules (Somekawa et al., 2005) and enhances
intracellular Ca2+ release during cardiac excitation-contraction
coupling (Pereira et al., 2007). A High throughput screening
assay to identify Epac inhibitors without affecting PKA activity
led Cheng and coworkers to the identification of ESI-05 as an
isoform specific inhibitor of Epac2 but not Epac1 (Tsalkova et al.,
2012) and ESI-09 an pan inhibitor of Epac1 and 2 (Almahariq
et al., 2013). CE3F4 compound (Courilleau et al., 2012) was
identified as a specific Epac1 inhibitor without influence on PKA
activity and its isoform selectivity for EPAC1 toward EPAC2 was
demonstrated later (Courilleau et al., 2013). CE3F4 could be of
interest in the therapeutic of cardiac pathophysiology as Epac1
is involved in β-adrenergic receptor-induced cardiomyocyte
hypertrophy (Métrich et al., 2008). The compound usually named
007 [8-(4-Chloro-phenylthio)-2’-O-methyl-cAMP] is a cAMP
analog activating Epac but not PKA (Enserink et al., 2002) but it
has to be noted that 007 can behave as an inhibitor of PDEs which
may indirectly increases cyclic nucleotide concentration (Poppe
et al., 2008).
CNGC Inhibitors
The family of cyclic nucleotide gated channels (CNGC)
comprises two groups: cyclic nucleotide gated (CNG)
channels and the hyperpolarization-activated cyclic nucleotide-
gated (HCN) channels. Both types are members of the six
transmembrane channel superfamily and contain a cyclic
nucleotide binding domain in their cytosolic C-Terminus
that serves as an activation domain. Upon cyclic nucleotide
binding, CNG channels gates the flow of monovalent cations
such as Na+ and K+ to cross the plasma membrane and have
a greater sensitivity for cGMP than for cAMP (for review
Podda and Grassi, 2014). HCN cations channels open upon
hyperpolarization and cAMP enhance their activity by shifting
the activation curve to more positive voltage (Scicchitano et al.,
2012). Four members exist in mammals (HCN1–HCN4) and
are known to regulate the If current to control heart rate and
rhythm by acting as a pacemaker current in the sinoatrial node
(Wahl-Schott et al., 2014). If current is regulated by various
neurotransmitters and metabolic stimuli (Pape, 1996) and are
promising pharmacological targets in the treatment of cardiac
arrhythmias. Thus, the most extensively studied HCN channels
blocker is ZD7288 (BoSmith et al., 1993) but If current can also
be blocked by ivabradine (Bucchi et al., 2002, 2006), zatebradine,
and cilobradine (Van Bogaert and Pittoors, 2003). Ivabradine
derivatives led to the discovery of HCN selective blockers with
EC18 identified as a selective blocker for HCN4 and MEL57A
induced mHCN1 inhibition (Melchiorre et al., 2010; Del Lungo
et al., 2012).
POPDC Inhibitor
The Popeye domain-containing gene family consists of 3 genes
(podc1, podc2, and popdc3) encoding a 3 transmembrane
proteins that bind cAMP through their conserved cytoplasmic
Popeye domain with an affinity (IC50) of 120 nM, which is
comparable to the affinities reported for PKA (100 nM) (Froese
et al., 2012). These proteins are essential for stress mediated
modulation of cardiac pacemaking (Froese et al., 2012; Schindler
et al., 2012). To our knowledge, no pharmacological inhibitors
have been reported to investigate specific POPDC protein
function so that the only way to modulate their activities so far
is the use of genetic tools (small interfering RNA technology or
gene knockout).
Methods for cAMP Detection in the
Cardiac Tissue
The number of technologies that enables the functional screening
of cAMP production has expanded over the years. Consequently,
the choice of the technology will define the scope of the
conclusions that can be drawn. Those methods can be divided
into two groups: the direct methods allowing an “absolute”
cAMP concentration quantification and the indirect methods
which give a relative representation of cAMP availability. Thus,
as summarized in Table 3, direct methods are generally more
sensitive than indirect one since lacking any mediator but
cannot accurately sense low cAMP levels produced in subcellular
compartments. The advantages and limits of the common
systems are listed below and basic principle for each technique is
shown on Table 3. As previously pinpointed, cAMP availability is
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TABLE 3 | Comparison of cAMP detection system.
Class Method Principle Localization Sensitivity Signal in presence of cAMP
Biochemical Radiometric Homogenate 10 nM ց
Fluorescence polarization Homogenate 10 nM ր
Enzyme or fluorescence detection Homogenate 1 nM ց
HTRF Homogenate 1 nM ց
AlphaScreen Homogenate 1 nM ց
Enzyme complementation Homogenate 1 nM ր
Electroluminescence Homogenate 1 nM ց
Integrative cAMP binding on circularly permutted luciferase Whole cell 100µM ր
CNGC based Whole cell nd ր
Reporter gene CRHB response element Whole cell nd ր
RET Based PKA based Cytosol ց
Epac based Plasma membrane ց
Endosome ց
Cytosol ց
CNGC based Membrane 0.1µM ց
Membrane 1µM ց
Membrane 50µM ց
Click chemistry Copper free Azide-alkaline cycloaddition Derivative cAMP syntesis nd ր
fine-tuned by a tight balance between its synthesis and immediate
hydrolysis/eﬄux/use so that at one time point, cAMP is not
enough amenable to quantification assays. Thus, accumulation
of cAMP is often mandatory in most of cAMP detection assays
with the common use of the pan PDEs inhibitor IBMX (when
cAMP production needs to be measured) or FSK pretreatment
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(when cAMP production inhibitory function wants to be
outlined).
Direct Methods: Biochemical Approaches
cAMP has been long quantified through a radioactive functional
assay based on affinity chromatography purification using 3H-
ATP-preloaded cells lysates. After lysis and cAMP production can
be estimated by measuring the ratio between 3H-cAMP over 3H-
ATP + 3H-cAMP separated on affinity column (Piñeyro et al.,
2005). Despite its high sensitivity, this technique often requires
the presence of PDEs inhibitor and is not suitable for high
throughput screening (HTS) strategy. Most of HTS biochemical
methods relies on the general principle that cAMP accumulation
is being detected by competition for a specific cAMP antibody
between free unlabelled cAMP present in the sample to evaluate
and a labeled form (radioactive, fluorescent, or enzymatic)
of cAMP (Williams, 2004). Radiometric assays allow detection
of cAMP using competition with 125-I labeled cAMP for anti-
cAMP antibody immobilized on a solid scintillant plate. In those
assays, the radiometric signal decreases proportionally to the
amount of cAMP present in the sample (Horton and Baxendale,
1995). Fluorescence polarization cAMP assays monitor the light
emitted from a fluorescent-tagged cAMP following excitation
by a polarized light source. When the labeled cAMP is
bound to an antibody more polarized light will be produced
upon excitation (Prystay et al., 2001; Huang et al., 2002). To
increase the signal to noise and to avoid cell autofluorescence
detection, Cisbio developed an HTRF (Homogeneous time
resolved fluorescence)-based cAMP assay. This assay is still
based on a competitive immunoassay using cryptate-labeled anti-
cAMP antibody and d2-labeled cAMP (Degorce et al., 2009).
Alpha-screen technology uses acceptor beads conjugated to an
antibody that recognizes cAMP and streptavidin-coated donor
beads. When brought into close proximity by the presence of
biotinylated cAMP, an oxygen radical dependent light is emitted.
The cAMP extracted from a cell lysate will compete with the
biotinylated cAMP and reduce the emitted light. This kind
of assay is also available with an enzymatic based detection
method where cAMP found in test sample competes with a
fixed amount of Horse Radish Peroxydase-linked cAMP for
binding to an anti-cAMP immobilized antibody (Bouchard
et al., 2006). The electroluminescence technique (Mesa Scale
Discovery) is another competitive immunoassay based on the
displacement of ruthenium-labeled cAMP for an anti-cAMP
antibody. The electrochemical reaction is initiated upon substrate
and electrical charge addition and produce light which is
inversely proportional to the cAMP present in the sample (Filip
et al., 2004). The immuno-based competition can also be revealed
using an enzyme complementation method (DiscoverX). In this
assay, a fragment of β-galactosidase (β-gal) is conjugated with
cAMP and act as an enzyme donor (ED) (Golla and Seethala,
2002). This ED-cAMP conjugate and cellular cAMP compete for
binding to an anti-cAMP antibody. In presence of the enzyme
acceptor (EA), the active enzyme will be reconstituted and
will be able to subsequently hydrolyze a substrate to produce
a chemiluminescent signal that is directly proportional to the
amount of cAMP in the cells. Despite being sensitive and specific,
all those techniques require cells or tissue disruption making
the real-time and sub-cellular analysis of cAMP quantification
impossible. Moreover if those assays are highly efficient to
measure cAMP production, their use to bring to the fore cAMP
inhibition is challenging and require FSK pretreatment.
Indirect Methods
Integrative Methods
Promega developed an assay based on the GloSensor Technology,
a genetically modified form of firefly luciferase into which a
cAMP-binding protein domain has been inserted (Fan et al.,
2008). The firefly luciferase is circularly permuted and upon
cAMP binding, a conformational change induces luciferase
enzyme reconstitution which produces light in presence of
its substrate. This technique is sensitive enough to assess
role of endogenous receptors but requires transfection of the
biosensor, thus limiting the quantification of the cAMP to
the transfection efficiency (expression heterogeneity between
cells) which can lead to high results variability. Maintaining
advantages of integrative methods (sensitivity and kinetic)
but avoiding transfection variability, Rivero-Müller’s group
developed a derived detection method CANDLES (Cyclic AMP
iNdirect Detection by Light Emission from Sensor cells). Briefly,
a stable cell line expressing a GloSensor plasmid is co-cultured
with cells expressing the receptor to be tested and through cell-
cell interaction via gap junctions, cAMP produced by the cell
of interest can be transferred to the sensor cells to activate
GloSensor plasmid (Trehan et al., 2014). Finally, given that the
GloSensor is a cytosolic probe, it could be not appropriate to
detect low concentrations of compartmentalized cAMP at the
plasma membrane.
Reporter Gene Methods
The reporter gene method is a homogeneous, simple and
inexpensive but indirect method to detect cAMP-downstream
signaling. This assay is based on the specific activation of the
transcription factor CREB (cAMP response element binding
protein) upon cAMP production which induces a reporter gene
under the control of a CRE element (cAMP Response Element)
promoter. Various reporter genes have been used over the years:
fluorescent proteins, luciferase, β-galactosidase or β-lactamase.
Far downstream of the cAMP activation cascade, this method is
sensitive but unable to give kinetics or localization information.
Resonance Energy Transfer Methods
The methods described above are unable to define the cellular
localizations of cAMP production. Thus, visualization was
achieved using resonance energy transfer (RET) techniques
described by the Theodor Förster in 1940’s (Forster, 1946).
RET is a mechanism relying on an energy transfer between
a donor chromophore that may transfer energy to another
acceptor chromophore through non-radiative dipole–dipole
coupling upon distances proximity conditions (Hebert et al.,
2006; Kiyokawa et al., 2006). The name FRET “Förster
resonance energy transfer” which includes the commonly used
term FRET “Fluorescence resonance energy transfer” and
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BRET “Bioluminescence resonance energy transfer” is a non-
radiative transfer of energy occurring between two fluorescent
chromophores for FRET or between an enzyme generating
luminescent signal upon addition of its substrate and a
fluorescent acceptor partner in the case of BRET technology. The
efficiency of this energy transfer is inversely proportional to the
sixth power of the distance between donor and acceptor, making
RET extremely sensitive to very small changes in distance thus
allowing an accurate sensing of change in protein conformations
for instance (Hebert et al., 2006). BRET is a first line assay for
HTS screening as it avoids the consequences of fluorescence
excitation and has a better Stokes’ shift over FRET but is not
recommended for imaging technique to identify localized cAMP
compartmentalization. Thus RET-based methods have been
developed to detect cAMP production and extensively reviewed
(Williams, 2004; Willoughby and Cooper, 2008; Sprenger and
Nikolaev, 2013; Calebiro and Maiellaro, 2014). All the methods
rely on the use of the downstream cAMP effectors PKA, Epac or
CNGC either that all directly bind cAMP molecules related to
the expression of a specific cAMP-binding motif. Briefly, either
full-length cAMP-effector probes or single cAMP domain sensor
extracted from the different effectors are fused to an energy
donor and acceptor allowing the generation of a basal RET signal
in the absence of cAMP production. Upon cAMP binding, a
conformational rearrangement in the RET-based sensor will lead
to a modification of the RET signal. Since the pioneering studies
using those RET probes to study cAMP availability in cardiac
tissue (Zaccolo et al., 2000; Zaccolo and Pozzan, 2002), many
efforts have been made these last years to improve signal to
noise ratio, RET efficiency (optimizing donor-acceptor couple,
linker optimization), cAMP binding affinity (mutagenesis on
single domain or full length protein probes), RET detection
methods (e.g., Sensitized emission vs Fluorescence lifetime
imaging microscopy for FRET-based probes, Renilla luciferase
variants for BRET-based probes) (Willoughby and Cooper, 2008;
Sprenger and Nikolaev, 2013). Moreover with the prominently
recognized mechanism for cAMP compartmentation, several
group restricted the expression of those RET based probes to
subcellular localization using for example plasma membrane
targeting sequence or endosome localization (Klarenbeek and
Jalink, 2014; Sprenger et al., 2015).
Copper Free Azide-alkaline Cycloaddition: a “Click
Chemistry”
In chemical synthesis, click chemistry is a process that generates
by joining small units together. The azide alkyne Huisgen
cycloaddition using a Copper (Cu) catalyst is one of the most
popular reactions within the Click chemistry concept between
an azide and a terminal or internal alkyne to give a 1,2,3-triazole
(Rostovtsev et al., 2002; Tornøe et al., 2002). To avoid Cu toxicity,
Baskin et al. developed a Cu-free click reaction with comparable
kinetics to Cu dependent cycloaddition, but adapted for dynamic
in vivo imaging (Baskin et al., 2007). In a recent study, this copper
free method was applied to detect cAMP derivative (8-azido
cAMP) in vivo after the addition of difluorinated cyclooctyne
(DIFO) as a reagent (Ito et al., 2013). If this approach will
enable to visualize and quantify derivative cAMP endogenous
modulators at the single cell level without exogenous transfection
protocol, it has to be noted that the molecule used is a
cAMP derivative so the signal observed will be the result of
FIGURE 4 | cAMP synthesis and hydrolysis: pharmacological way to modulate its availability.
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ACs/PDEs activities in competition with cAMP endogenously
produced.
Conclusion
The development of optical methods that allow monitoring of
cAMP dependent signaling in living cells and the growing list of
molecules (summarized in Figure 4) available to modulate cAMP
availability played a fundamental role in revealing an unexpected
level of cAMP organization in cardiac tissue. It is likely
that new optical methods development, with higher temporal
and spatial resolution, will improve our knowledge of cAMP
dependent signaling microdomains located on the cell surface or
other intracellular membranes for individual cells within heart
architecture.
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